Serum calgranulin C as a non-invasive predictor of activity among inflammatory bowel disease….. Original Research Article…..

The Egyptian Journal of Immunology
E-ISSN (2090-2506)
Volume 31 (3), July, 2024
Pages: 81–94.
www.Ejimmunology.org
https://doi.org/10.55133/eji.310309
Hany S. Rasmy, Noha A. Elnakeeb, Mohamed F. Mohamed, and Hossam S. Elbaz
Department of Internal Medicine, Hepatology & Gastroenterology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Corresponding author:
Hany S. Rasmy, Department of Internal Medicine, Hepatology & Gastroenterology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Email: hanysamir@med.asu.edu.eg.

 

Abstract

Inflammatory bowel disease is a chronic immune-mediated disorder with a relapsing and remitting course. It leads to disabling gastrointestinal symptoms, low quality of life, and a significant burden for healthcare utilization and associated costs. Therefore, non-invasive biomarkers are needed for early diagnosis and follow up to avoid the complications of invasive diagnostic procedures. Calgranulin C is a calcium binding protein with proinflammatory properties. The aim of this study was to evaluate the role of serum calgranulin C as a non-invasive biomarker for diagnosis and prediction of activity in comparison to different biomarkers and endoscopic activity scores in inflammatory bowel disease. The study included 80 inflammatory bowel disease patients (50 Ulcerative colitis and 30 Chron’s patients) and 20 normal controls. Complete blood picture, C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin and serum calgranulin C were measured. Colonoscopies with histopathological examination were done and different activity scoring systems assessed. Among ulcerative colitis group, serum calgranulin C was statistically significantly higher in comparison to control group [723.640±529.055 ng/ml versus 80.850±24.416 ng/ml]. Depending on the American college of gastroenterology ulcerative colitis activity index, fecal calprotectin and serum calgranulin C were statistically significantly higher among moderate to severe ulcerative colitis than those with mild activity and those in remission (p <0.001, for both). Regarding Crohn’s disease group, serum calgranulin C was statistically significantly higher in comparison to control group [759.233±797.963 ng/ml versus 80.850±24.416 ng/mL]. Depending on Crohn’s disease activity index, both serum calgranulin C and fecal calprotectin were statistically significantly higher among active disease than those in remission (p <0.001, for both). In conclusion, serum calgranulin C could be used as a non-invasive marker to predict activity and severity and to ensure remission among inflammatory bowel disease patients.

Keywords:
Serum calgranulin C, Ulcerative colitis, Crohn’s disease, inflammatory bowel disease.

Date received: 14 December 2023; accepted: 13 June 2024

PMID:
38995671

 

Full Text